Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Амлодипин в лечении сердечно-сосудистой патологии: доказанные антигипертензивный и антиатеросклеротический эффекты
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Андреев Н.А., Моисеев В.С. Антагонисты кальция в клинической медицине. М.: ФАРМЕДИНФО, 1995.
2. Гилман А.Г. Клиническая фармакология по Гудману и Гилману. М.: Практика, 2006.
3. Blood Pressure Lowering Yreatment Trialists` Collaboration. Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overvieus of randomized trials. Lancet 2000; 356: 1949–54.
4. Nayler WG. Calcium antagonists. London: Academic press, 1988.
5. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan – or amlodipine – based regimens: VALUE, a randomised trial. Lancet 2004; 363: 366–372.
6. Dalhöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in Anglo-Scandinavian Cardiac Outcome Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
7. Muiesan L, Salvetti M, Monteduro C. Effect of Treatment on Flow Depended Vasodilatation of the Brachial Artery in Essential Hypertension 1999; 33: 575–80.
8. Schiffrin B, Pu Q, Park JB. Effect of amlodiopine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002; 15 (2 Pt 1): 105–10.
9. Zhang X, Kichuk MR, Mital S et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary vicrovessels of falling human hearts. Am J Cardiol 1999; 84: 27L–33L.
10. Pitt B, Buington RP, Fuberg CL et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
11. O`Leary DH, Polak JF, Kronmal RA et al. Carodtid-artery intima thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.
12. Jorgensen B, Simonsen S, Endresen K et al Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592–9.
13. Mason RP Mechanism of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002; 165: 191–9.
14. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
15. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. (от имени исследователей). Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваскулярная терапия и профилактика. 2010; 6: 47–56.
2. Гилман А.Г. Клиническая фармакология по Гудману и Гилману. М.: Практика, 2006.
3. Blood Pressure Lowering Yreatment Trialists` Collaboration. Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overvieus of randomized trials. Lancet 2000; 356: 1949–54.
4. Nayler WG. Calcium antagonists. London: Academic press, 1988.
5. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan – or amlodipine – based regimens: VALUE, a randomised trial. Lancet 2004; 363: 366–372.
6. Dalhöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in Anglo-Scandinavian Cardiac Outcome Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
7. Muiesan L, Salvetti M, Monteduro C. Effect of Treatment on Flow Depended Vasodilatation of the Brachial Artery in Essential Hypertension 1999; 33: 575–80.
8. Schiffrin B, Pu Q, Park JB. Effect of amlodiopine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002; 15 (2 Pt 1): 105–10.
9. Zhang X, Kichuk MR, Mital S et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary vicrovessels of falling human hearts. Am J Cardiol 1999; 84: 27L–33L.
10. Pitt B, Buington RP, Fuberg CL et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
11. O`Leary DH, Polak JF, Kronmal RA et al. Carodtid-artery intima thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.
12. Jorgensen B, Simonsen S, Endresen K et al Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592–9.
13. Mason RP Mechanism of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002; 165: 191–9.
14. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
15. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. (от имени исследователей). Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваскулярная терапия и профилактика. 2010; 6: 47–56.
Авторы
М.Г.Бубнова
ФГУ ГНИЦ профилактической медицины Минздравсоцразвития РФ
Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
ФГУ ГНИЦ профилактической медицины Минздравсоцразвития РФ
Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.